Secukinumab Proves Successful in Treating Severe HS, Safety

In a recent study, secukinumab therapy demonstrated adequate safety and efficacy profiles, offering potential benefits for patients with severe hidradenitis suppurativa (HS) who found adalimumab intolerable.

Related Keywords

, Investigational Dermatology , Hidradenitis Suppurativa Clinical Response ,